ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1839 • ACR Convergence 2024

    PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways

    Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
  • Abstract Number: 2232 • ACR Convergence 2024

    Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Nicole Wilson5, Susan Manzi5, Veena Joy6 and Tyler O'Malley7, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6ThermoFisher, Philadelphia, PA, 7Exagen, Vista, CA

    Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
  • Abstract Number: 2400 • ACR Convergence 2024

    Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts

    Melissa Fazzari1, Jane Salmon2, Marta Guerra2, Nathalie Costedoat-Chalumeau3, Veronique LE GUERN4, Gaëlle Guettrot-Imbert4, Marta Mosca5, Dina Zucchi6, Chiara Tani7, Rebecca Fischer-Betz8, Isabell Haase9, Anna Broder10, Navneet Kaur11, Jill Buyon12, Brooke Cohen12, Diane Kamen13, Jessica English14, Anna Arar13 and Mimi Kim15, 1Albert Einstein College of Medicine, Bronx, NY, 2Hospital for Special Surgery, New York, NY, 3Inserm DR Paris 5, Paris, France, 4Cochin hospital, Paris, France, 5University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 6Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 7University of Pisa, Pisa, Italy, 8Uniklinik Düsseldorf, Düsseldorf, Germany, 9Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, 10Hackensack Network, Hackensack, NJ, 11Touro University Medical Group, Sacramento, CA, 12NYU Grossman School of Medicine, New York, NY, 13Medical University of South Carolina, Charleston, SC, 14Medical University of South Carolina, Johns Island, SC, 15Albert Einstein College of Medicine, Larchmont, NY

    Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
  • Abstract Number: 2594 • ACR Convergence 2024

    A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways

    Saul Kivimae1, Sandip Mukherjee2, Phi Quach3, Rhoneil Pena4, Olga Zemska3, Michal Olszewski5, Jicai Huang3, Michael Labson6, Donald Walker1, Mekhala Maiti7, Chakrapani Tripathi8, Thomas Chang3, Suresh Adapala9, Damon Hamel3, Katherine Brendza3, Takahiro Miyazaki3 and Jonathan Zalevsky1, 1Nektar Therapeutics, San Francisco, CA, 2Nurix Therapeutics, San Francisco, 3Nektar Therapeutics, San Francisco, 4Sutro Biopharma, South San Francisco, 5Vaxcyte, San Francisco, 6Guardant Health, Palo Alto, 7Alumis, Inc, South San Francisco, 8Theragent Inc, Arcadia, CA, 9Inotiv, Rockville, MD

    Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
  • Abstract Number: 0319 • ACR Convergence 2024

    Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

    Farbod Moghaddam1, Mark Tarnopolsky2, Valérie Leclair3, marie Hudson3, Ross Mitchell4, Katherine Buhler1, Erin Hatcher5, Meifeng Zhang1, Antoine Dufour1, Luiz de Almeida1, Marvin Fritzler6 and May Choi1, 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, Canada, 5McMaster University, Hamilton, Canada, 6Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
  • Abstract Number: 0491 • ACR Convergence 2024

    Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis

    Jiayi Xu1, Yi Zhao2, Chenxi Zhu3, Yi Liu4, Tao Chen1, Rui Sun3, Huifang Hu5, Zhen Zhou1 and Yan Liu1, 1Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Cheng du, China (People's Republic), 2Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic), 3Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), 4Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, 5Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Chengdu, Sichuan, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…
  • Abstract Number: 0636 • ACR Convergence 2024

    Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)

    Danielle Egypto1, Edgard Reis Neto2, Guilherme Carlesso3, Luis Andrade4, Luiz Moura3, Debora Calderaro5 and Emília Sato6, and Emília Inoue Sato; Edgar Torres dos Reis Neto., 1Federal University of Paraiba, JOÃO PESSOA, Paraiba, Brazil, 2Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil, 3Federal University of São Paulo, São Paulo, SP, Brazil, 4Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, SP, Brazil, 5Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 6Universidade Federal de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…
  • Abstract Number: 0738 • ACR Convergence 2024

    Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA

    Colm Kirby1, Rachael Flood1, Sharon Cowley2, Emma Finlay3, Ronan Mullan1, Grainne Murphy4 and David Kane5, 1Tallaght University Hospital, DUBLIN, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3School of Biotechnology, Dublin City University, Dublin, Ireland, 4Cork University Hospital, Cork, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland

    Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…
  • Abstract Number: 0871 • ACR Convergence 2024

    Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”

    Juergen Rech1, Prof. Dr. Andreas Hess2, Koray Tascilar1, Dr. Hannah Schenker3, verena schönau1, Marina Sergeeva2, Jutta Prade2, Silke Kreitz2, Mageshva Sulvakumar2, Laura Konerth2, Sandra Strobelt2, Matthias Englbrecht4, Prof. Dr. Dr. Axel Hueber5, Eugen Feist6, Prof. Dr. Mario Zaiss1, Gerd Burmester7, Frank Behrens8, Dr. Michaela Koehm9, Prof. Dr. Christoph Baerwald10, Dr. Stephanie Finzel11, Dr. Arnd Kleyer12, Prof. Dr. Reinhard Voll11, Dr. Julie Roesch13, Prof. Dr. Arnd Doerfler13, Prof. Dr. Nemanja Damjanov14, Prof. José António P. Da Silva15 and Georg Schett16, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Institute for Experimental Pharmacology FAU Erlangen-Nürnberg, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Department of Internal Medicine 1 - Gastroenterology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Freelance Healthcare Data Scientist, Eckental, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, + Rheumatologie, Klinik für Innere Medizin 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland, Erlangen, Germany, 6Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 9Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, 10Medizinische Klinik III - Bereich Rheumatologie, Liebigstraße 20, 04103 Leipzig, Leipzig, Germany, 11Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Hugstetterstraße 55, 79106 Freiburg, Freiburg, Germany, 12Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Charité - Universitätsmedizin Berlin Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Berlin, Erlangen, Germany, 13Department of Neuroradiology, Friedrich - Alexander - Universitaet Erlangen - Nuernberg and Universitaetsklinikum Erlangen , Erlangen , Germany, Erlangen, Germany, 14Belgrade University School of Medicine, Institute Institute of Rheumatology, Belgrade, Belgrade, Serbia, 15Head of Department Reumatologia. Hospitais da Universidade (SRHUC), Coimbra, Portugal, 16Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…
  • Abstract Number: 1121 • ACR Convergence 2024

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases

    Alan Kivitz1, Stanley Cohen2, Annie Lau-Kilby3, Yajing Sun3, Jiayin Huang3, Atasi Jana3, Susie Kim3, Yanping Wu3, Quinnie Yang3 and Lin Zhao3, 1Altoona Center for Clinical Research, Duncansville, PA, 2Metroplex Clinical Research Center, dallas, TX, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…
  • Abstract Number: 1359 • ACR Convergence 2024

    Association of Coronary Artery Calcium Score and Growth Differentiation Factor 15 in Rheumatoid Arthritis

    Jessica Roldan Ortega1, Francisco Castillo-Castellon2, Evelyn Aranda Cano3, Luz Angelica Viruel-Mejia4, Itzel Palafox Sosa5, David Vera Bustamante6, Fausto Sánchez Muñoz2, ⁠Yaneli Juárez-Vicuña7, Luis H. Silveira Torre8 and Laura Aline Martinez-Martinez9, 1Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 2Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 3Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, 4Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, 5Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, 6Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, 7Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, 8Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 9Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Cardiovascular diseases are the leading cause of death in RA patients [Gravallese EM, Firestein GS. N Engl J Med. 2023;388:529-42]. However, risk calculation has…
  • Abstract Number: 1642 • ACR Convergence 2024

    A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis

    Andrea Fava1, Andrew Concoff2, Tyler O'Malley3, Sepehr Taghavi4, Touba Warsi4, Sudha Kumar4, Christine Schleif4 and Michelle Petri5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Vista, CA, 4Exagen, Carlsbad, CA, 5Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
  • Abstract Number: 1849 • ACR Convergence 2024

    Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis

    Theodora Manolakou1, Sanjaykumar Boddul1, George Sentis2, Michail Angelos Panagias1, Martina Samiotaki3, Dionysis Nikolopoulos1, Ana Slipicevic1, Kumar Sanjiv1, Martin Henriksson1, Oliver Mortusewicz1, Aikaterini Chatzidionysiou1, Per-Johan Jakobsson1 and Thomas Helleday1, 1Karolinska Institutet, Stockholm, Sweden, 2Biomedical Reseearch Foundation Academy of Athens, Athens, Greece, 3Alexander Fleming Biomedical Sciences Research Center, Athens, Greece

    Background/Purpose: Rapidly proliferating cells fuel their increased nucleotide demand by boosting one-carbon metabolism, associated with the survival of pathogenic proliferative cells and the release of…
  • Abstract Number: 2233 • ACR Convergence 2024

    Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Susan Manzi5, Michael Mahler6, Veena Joy7 and Tyler O'Malley8, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Werfen, San Diego, CA, 7ThermoFisher, Philadelphia, PA, 8Exagen, Vista, CA

    Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
  • Abstract Number: 2423 • ACR Convergence 2024

    Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus

    Alice Horisberger1, Katharina Shaw2, Eilish Dillon3, Kathryne Marks4, Rochelle Castillo5, Ifeoluwakiisi Adejorin6, Kimberly Hashemi4, Karen Costenbader7, Avery LaChance8, Ruth Ann Vleugels5 and Deepak Rao1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Perelman School of Medicine at the University of Pennsylvania, Merion Station, PA, 3University of Massachusetts Boston, Yarmouth, MA, 4Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital, Jamaica Plain, MA

    Background/Purpose: Anifrolumab, a monoclonal antibody targeting type I interferon (IFN-I) receptor subunit 1, was recently approved for the treatment of systemic lupus erythematosus (SLE) and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology